These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19297194)

  • 21. M2e-based universal influenza A vaccine.
    Fiers W; De Filette M; El Bakkouri K; Schepens B; Roose K; Schotsaert M; Birkett A; Saelens X
    Vaccine; 2009 Oct; 27(45):6280-3. PubMed ID: 19840661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflexal V--the influenza vaccine with the lowest ovalbumin content.
    Kürsteiner O; Moser C; Lazar H; Durrer P
    Vaccine; 2006 Nov; 24(44-46):6632-5. PubMed ID: 16828206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insect cells as a new substrate for vaccine production.
    Dalemans W
    Dev Biol (Basel); 2006; 123():235-41; discussion 265-6. PubMed ID: 16566449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin.
    Schwarzer J; Rapp E; Hennig R; Genzel Y; Jordan I; Sandig V; Reichl U
    Vaccine; 2009 Jul; 27(32):4325-36. PubMed ID: 19410619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
    Szymczakiewicz-Multanowska A; Groth N; Bugarini R; Lattanzi M; Casula D; Hilbert A; Tsai T; Podda A
    J Infect Dis; 2009 Sep; 200(6):841-8. PubMed ID: 19673651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
    Reisinger KS; Block SL; Izu A; Groth N; Holmes SJ
    J Infect Dis; 2009 Sep; 200(6):849-57. PubMed ID: 19673652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
    Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
    Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a low-cost, insect larvae-derived recombinant subunit vaccine against RHDV.
    Pérez-Filgueira DM; Resino-Talaván P; Cubillos C; Angulo I; Barderas MG; Barcena J; Escribano JM
    Virology; 2007 Aug; 364(2):422-30. PubMed ID: 17434554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The future of cell culture-based influenza vaccine production.
    Perdue ML; Arnold F; Li S; Donabedian A; Cioce V; Warf T; Huebner R
    Expert Rev Vaccines; 2011 Aug; 10(8):1183-94. PubMed ID: 21854311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of a decrease in potency for the recombinant influenza A virus hemagglutinin H3 antigen during storage.
    Hickey JM; Holtz KM; Manikwar P; Joshi SB; McPherson CE; Buckland B; Srivastava IK; Middaugh CR; Volkin DB
    J Pharm Sci; 2014 Mar; 103(3):821-7. PubMed ID: 24425059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens.
    Wu Q; Fang L; Wu X; Li B; Luo R; Yu Z; Jin M; Chen H; Xiao S
    Mol Immunol; 2009 Jul; 46(11-12):2210-7. PubMed ID: 19446339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a simple and high-yielding fed-batch process for the production of influenza vaccines.
    Meghrous J; Mahmoud W; Jacob D; Chubet R; Cox M; Kamen AA
    Vaccine; 2009 Dec; 28(2):309-16. PubMed ID: 19879996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.
    Koudstaal W; Hartgroves L; Havenga M; Legastelois I; Ophorst C; Sieuwerts M; Zuijdgeest D; Vogels R; Custers J; de Boer-Luijtze E; de Leeuw O; Cornelissen L; Goudsmit J; Barclay W
    Vaccine; 2009 Apr; 27(19):2588-93. PubMed ID: 19428865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Las vacunas de la gripe basadas en las partículas
    Reina J
    Vacunas; 2012; 13(2):64-68. PubMed ID: 32288700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of MDCK cells for production of live attenuated influenza vaccine.
    Liu J; Shi X; Schwartz R; Kemble G
    Vaccine; 2009 Oct; 27(46):6460-3. PubMed ID: 19559113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insect cell technology is a versatile and robust vaccine manufacturing platform.
    Mena JA; Kamen AA
    Expert Rev Vaccines; 2011 Jul; 10(7):1063-81. PubMed ID: 21806400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternative influenza vaccines made by insect cells.
    Krammer F; Grabherr R
    Trends Mol Med; 2010 Jul; 16(7):313-20. PubMed ID: 20570562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status and progress of prepandemic and pandemic influenza vaccine development.
    Leroux-Roels I; Leroux-Roels G
    Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.